Administration of AF-EVs in the early stage of injury, improved lung tissue structure, reduced macrophage infiltration, and reduced expression of pro-inflammatory cytokines: IL1a, IL1b, MCP-1, and MIP-1a (6). The gene discussed is CCL2; the disease is atrial fibrillation.